58,766 results match your criteria: "Hodgkin Disease"
Clin Pharmacokinet
December 2024
Clinical Pharmacology and Quantitative Science, Genmab, Plainsboro, NJ, USA.
Background And Objectives: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL.
Methods: Plasma concentration-time data included 6819 quantifiable pharmacokinetic samples from 327 patients with R/R B-NHL.
Virchows Arch
December 2024
Institute of Pathology and Neuropathology, Eberhard Karls University of Tuebingen and Comprehensive Cancer Center, University Hospital Tuebingen, Liebermeisterstr. 8, 72076, Tuebingen, Germany.
Only 10% of new lymphoma diagnoses in the USA occur in children < 15 years. Although the same diagnostic criteria apply to both adult and pediatric lymphomas, there are important differences in some lymphoma subtypes. These differences are recognized by the World Health Organization (WHO) with the recent 2022 classification of pediatric tumors including pediatric hematopoietic tumors.
View Article and Find Full Text PDFLeukemia
December 2024
Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide. To discover risk factors and pathogenesis of DLBCL, we performed the largest GWAS of DLBCL to date in samples of East Asian ancestry, consisting of 2,888 patients with DLBCL and 12,458 controls. The meta-analysis identified three novel loci, rs2233434 on 6p21.
View Article and Find Full Text PDFLeuk Lymphoma
December 2024
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Despite increasing utilization of CAR T-cell therapy, data are lacking regarding long term follow up and risk of infectious complications after the early period following CAR T-cell infusion. In this study, we sought to compare epidemiology and risk factors for early (≤ 3 months) and late (3 months to 1 year) infections. Data were retrospectively collected at six time points: pre-CAR T, day of infusion, and at 3, 6, 9, and 12 months post CAR-T infusion for all consecutive adult patients treated at our institution.
View Article and Find Full Text PDFStem Cells
December 2024
Department of Psychiatry, University of Oxford, Headington, Oxford OX3 7JX, UK.
Human induced pluripotent stem cells (iPSCs) provide powerful cellular models of Alzheimer's disease (AD) and offer many advantages over non-human models, including the potential to reflect variation in individual-specific pathophysiology and clinical symptoms. Previous studies have demonstrated that iPSC-neurons from individuals with Alzheimer's disease (AD) reflect clinical markers, including β-amyloid (Aβ) levels and synaptic vulnerability. However, despite neuronal loss being a key hallmark of AD pathology, many risk genes are predominantly expressed in glia, highlighting them as potential therapeutic targets.
View Article and Find Full Text PDFPlasma metabolomics analysis was performed on 44 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r/B-NHL) infused with approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and at day +1, +7, and +30 after CAR-T cell infusion. At the PLD time point, a metabolic profile characterized by high lipoproteins and lactate and low glucose contributed to poor outcome prediction in association with high lactate dehydrogenase levels.
View Article and Find Full Text PDFFront Oncol
December 2024
Department of Geriatrics, Hematology & Oncology Ward, Guangzhou First People's Hospital, Guangdong Medical University, Guangzhou, Guangdong, China.
Hodgkin lymphoma variant of Richter syndrome (HL-type RS) is a very rare disease, in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) is transformed into novel Hodgkin lymphoma. The most important prognostic factor of HL-type RS is the clonal relationship between HL-type RS and the preexisting CLL/SLL. Detailed confirmation of clonally unrelated HL-type RS cases have not been reported.
View Article and Find Full Text PDFTransl Cancer Res
November 2024
School of Life Sciences, Jiangsu University, Zhenjiang, China.
Background: Head and neck squamous cell carcinoma (HNSCC) contributes significantly to global health challenges, presenting primarily in the oral cavity, pharynx, nasopharynx, and larynx. HNSCC has a high propensity for lymphatic metastasis. Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, exhibits significant heterogeneity and aggressive behavior, leading to high mortality rates.
View Article and Find Full Text PDFJ Hematol
December 2024
Division of Hematology and Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
Background: CD20-targeted therapies are widely used in the management of B-cell lymphomas. Re-treatment with CD20-directed agents is common; however, previous research has demonstrated loss of CD20 expression at relapse in a subset of patients.
Methods: In this single-center retrospective cohort of 243 patients, CD20 analysis was performed by immunohistochemistry (IHC) and/or flow cytometry at diagnosis and at relapse if a biopsy was performed.
J Med Case Rep
December 2024
Department of Oral Surgery, Faculty of Dentistry, Mohammed V University, Rabat, Morocco.
Introduction: Burkitt lymphoma is an aggressive form of non-Hodgkin B cell lymphoma. Oral lesions often are a component of the disseminated disease process that may involve regional lymph nodes or may at times represent the primary extranodal form of the disease. However, isolated oral Burkitt lymphoma in adults is extremely rare.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
December 2024
Department of Clinical Investigation and Clinical Epidemiology, AP-HP-Centre-Université Paris Cité, Hôpital Européen Georges Pompidou, Paris, France; Department of Gastroenterology, AP-HP. Centre- Université Paris Cité, Hôpital Cochin, Paris, France. Electronic address:
Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is highly effective in B-cell blood cancers, but there is limited data on its safety and efficacy in intra-cardiac lymphoma, due to the potential risks of cardiotoxicity and pseudo-progression.
Discussion: We discuss four high-risk cases that were managed with a multi-disciplinary approach, including baseline cardiac risk assessment and surveillance with multimodal cardiac imaging and serum cardiac biomarkers, elective supportive care in the intensive care unit, and early treatment of cytokine release syndrome.
Conclusion: CAR-T therapy can be effective and safe in the treatment of B-cell blood cancers with intra-cardiac disease.
Leuk Res
December 2024
Laboratory of Hemato-Immunology, Graduate School of Health Sciences, University of the Ryukyus, Nishihara, Japan.
Int J Mol Sci
December 2024
Host Microbiome Interaction, Clinical Pharmacology and Therapeutics, Institute of Pharmaceutical Science, King's College London, London SE1 9NH, UK.
Epidemiological and eradication trial evidence indicates that , a major causative factor in peptic ulcer and gastric cancer, is a driver of the hypokinesia of Parkinson's disease (PD). Psychological (cognitive impairment, depression and anxiety) and gastrointestinal (peptic ulceration and constipation) PD features can precede the symptomatic onset of motor features by decades. We hypothesise that the non- (NHPH), which have farm, companion and wild animals as their main hosts, can have a role in PD aetiopathogenesis.
View Article and Find Full Text PDFInt J Cancer
December 2024
Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Smokeless tobacco (SLT) use is an established carcinogen to the nasal cavity, lip, and oropharynx, however, few studies have examined cancer risks in older African women among whom SLT use is common. We investigated snuff use and the risk of site-specific cancers among 15,336 newly diagnosed female cancer patients in the Johannesburg Cancer Study, South Africa. We designed case-control comparisons across multiple cancer outcomes: (a) known SLT-associated cancers; (b) other tobacco-related cancers and (c) genital cancers owing to intravaginal snuff use.
View Article and Find Full Text PDFEClinicalMedicine
December 2024
Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Background: There is a significant association between low vitamin D levels at diagnosis of indolent B-cell lymphomas and inferior overall survival (OS). To determine whether supplemental vitamin D improves event-free survival (EFS) in these patients, we conducted a comparative double-blind study of vitamin D vs. placebo.
View Article and Find Full Text PDFCureus
November 2024
Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA.
Hypercalcemia is a common metabolic complication associated with malignancies, particularly in solid tumors, such as lung and breast cancers. However, its occurrence in hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), is rare. The pathophysiology of hypercalcemia in lymphomas is often related to the secretion of parathyroid hormone (PTH)-related peptide (PTHrP).
View Article and Find Full Text PDFJ Assoc Physicians India
December 2024
Medical Graduate, Department of Surgery, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India, Corresponding Author.
Unlabelled: Introduction and importance: High-grade B-cell lymphoma (HGBCL) is a highly aggressive form of B-cell non-Hodgkin lymphoma. Lymphoma involvement of the gallbladder is rare, with a reported incidence of 0.1-0.
View Article and Find Full Text PDFSemin Radiat Oncol
January 2025
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, NJ.. Electronic address:
Lymphoma in elderly patients has unique treatment challenges due to baseline co-morbidities, nutrition status, impairment in functional capacities and fitness. While geriatric-specific assessment can be used to tailor treatment decisions, lack of adequate representation of elderly patients in lymphoma clinical trials impairs generalizability. Radiation treatment has traditionally been associated with high response and local control for lymphomas.
View Article and Find Full Text PDFSemin Radiat Oncol
January 2025
Department of Radiation Oncology, Stanford University, Stanford, CA.
Immune checkpoint inhibitors have transformed the future management of classic Hodgkin lymphoma (CHL) in the frontline and salvage settings. Both nivolumab and pembrolizumab have high efficacy in CHL allowing for reduction of chemotherapy and possibly the use of radiotherapy based on short-term follow-up. In this review article, we highlight recent trials enrolling patients with relapse and refractory classic Hodgkin lymphoma receiving monotherapy with PD-1 inhibitors as well as PD-1 and chemotherapy regimens.
View Article and Find Full Text PDFSemin Radiat Oncol
January 2025
Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
The role of radiotherapy in the treatment of lymphoma is rapidly evolving. The development of modern systemic therapies and the adoption of FDG-PET-scanning as metabolic prognosticators are leading to a process of refinement of the treatment regimens. In this scenario, radiotherapy utilization is decreasing in several settings, including lower risk patients, to prevent the risk of long-term complications.
View Article and Find Full Text PDFAnn Hematol
December 2024
Medical Center of Hematology, Xinqiao Hospital, Army Medical University, No.83 Xinqiao Road, Chongqing, 400037, China.
Primary head and neck lymphoid neoplasms(PHNLN) are described as a series of lymphoid system-derived neoplasms which originally arising from head and neck region. Our study is aimed to present a panoramic view of PHNLN among adolescent and young adult(AYA) patients aged from 15 to 39 years-old. The individual patient information was obtained from Surveillance, Epidemiology and End Results(SEER) database.
View Article and Find Full Text PDFBMJ Case Rep
December 2024
Section of Gastroenterology, Cardinal Santos Medical Center, San Juan City, Philippines.
Primary gastrointestinal tract lymphoma (PGIL) is a rare form of presentation of gastrointestinal tract (GI) lymphomas. Inflammatory bowel disease (IBD) and the use of thiopurines are known risk factors for its appearance. We report a male patient in his early 70s treated only with mesalamine for ulcerative colitis (UC) for the past 6 years.
View Article and Find Full Text PDFPurpose: We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).
Methods: Patients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle.
Front Immunol
December 2024
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
RTX was initially used for non-Hodgkin's lymphoma treatment and has been used in the clinical treatment of various autoimmune diseases as well as in antirejection and immune induction therapy for kidney transplant recipients. Following RTX treatment, the time for B cell regeneration varies among patients, but there is no unified recommendation for the frequency of B cell monitoring. This study aimed to investigate the clinical significance of periodic monitoring of peripheral blood B lymphocytes in individualized immunotherapy following rituximab (RTX) treatment in patients with different diseases.
View Article and Find Full Text PDF